ArticleStem cell reviews and reports2026
Optimizing the Method for Differentiation of Functional Platelets from Human Induced Pluripotent Stem Cells.
Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThe global shortage of platelets presents a significant challenge in healthcare. Although human induced pluripotent stem cells (hiPSCs) offer a renewable source for ex vivo platelet production, the current approach remains constrained by heterogeneity, low yield, and high costs. This study introduces an optimized differentiation scheme (ODS) to improve ex vivo platelet differentiation from hiPSCs.
methodsA systematically optimized culture protocol was developed, incorporating: (1) a higher initial dose of embryoid body (EB) cells, (2) refining culture medium, (3) substitution of cytokines with small molecules, and (4) enhancement of megakaryocyte (MK) polyploidization via small-molecule supplementation. Feasibility and effectiveness were evaluated using microscopy, cell counting, flow cytometry, Wright-Giemsa staining, immunofluorescence (IF), and transmission electron microscopy (TEM).
resultsIncreasing the initial EB cell count significantly promoted megakaryocyte production and accelerated the process. A serum-free medium supplemented with human platelet lysate (HPL) was favorable for megakaryocyte generation. Small molecules 740Y-P and butyzamide effectively substituted SCF and TPO for differentiation, while the combination of blebbistatin and 616452 enhanced megakaryocyte maturation. Mature megakaryocytes continuously generated functional platelets that, upon thrombin activation, facilitated fibrin clot formation and contraction in vitro. This method shortened differentiation to 19 days, enhanced output to 1.42 CD41⁺ megakaryocytes and 14.9 platelets per iPSC, and reduced costs by 58.3%.
conclusionWe have established a cost-effective strategy for platelet production via hiPSC differentiation, with potential applications in cell therapy and gene editing.
Indexed as
Identifiers
41615641What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.